INSMED INC (INSM)

US4576693075 - Common Stock

67.99  +3.28 (+5.07%)

After market: 67.89 -0.1 (-0.15%)

News Image
16 days ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
18 days ago - Insmed Incorporated

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
19 days ago - InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in June 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

News Image
24 days ago - Insmed Incorporated

Insmed to Host Commercial Webinar on June 4, 2024

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
24 days ago - Insmed Incorporated

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
25 days ago - Insmed Incorporated

Insmed Announces Proposed $500 Million Public Offering of Common Stock

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
26 days ago - InvestorPlace

Why Is P3 Health Partners (PIII) Stock Down 4% Today?

P3 Health Partners stock is down on Tuesday after telling PIII investors about an offering of its shares to institutional investors.

News Image
26 days ago - Investor's Business Daily

Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market

The company could be the first to the finish line with a treatment for non-cystic fibrosis bronchiectasis.

News Image
26 days ago - InvestorPlace

Why Is Marpai (MRAI) Stock Down 41% Today?

Marpai stock is falling hard on Tuesday following news that shares of MRAI are going to be delisted from the Nasdaq Exchange tomorrow.

News Image
26 days ago - InvestorPlace

Why Is Insmed (INSM) Stock Up 134% Today?

Insmed stock is up on Tuesday with heavy trading of INSM shares alongside positive results from a Phase 3 clinical trial.

News Image
26 days ago - Bloomberg

Insmed Shares Surge After Drug Eases Lung Disease Symptoms

Insmed Inc. shares almost tripled after the company’s experimental drug reduced episodes of worsening symptoms in a final-stage study of patients with a rare lung condition.

News Image
26 days ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic as investors return to trading on Tuesday following the long holiday weekend!

News Image
26 days ago - Insmed Incorporated

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in...

News Image
a month ago - Insmed Incorporated

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
a month ago - Market News Video

Relative Strength Alert For Insmed

News Image
a month ago - Insmed Incorporated

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International

—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based...

News Image
a month ago - BusinessInsider

INSM Stock Earnings: Insmed Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insmed (NASDAQ:INSM) just reported results for the first quarter of 2024.Insmed...

News Image
a month ago - InvestorPlace

INSM Stock Earnings: Insmed Beats EPS, Misses Revenue for Q1 2024

INSM stock results show that Insmed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image
a month ago - Insmed Incorporated

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update

— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First...

News Image
2 months ago - Insmed Incorporated

Insmed To Present at the BofA Securities Health Care Conference 2024

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
2 months ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...